Dr. Duma is originally from Venezuela, born of a Colombian mother and Dominican father. She completed her internal medicine residency in Rutgers NJMS and fellowship at the Mayo Clinic in Rochester, Minnesota. Dr. Duma's clinical interests include the care of women with lung cancer, including their unique aspects of cancer survivorship. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. She also has opened the first clinic in the Midwest dedicated to women with lung cancer only. Apart from her clinical interests in lung cancer, she is also a leading and productive researcher in gender and racial discrimination in medical education and medicine. She has been awarded several awards, including the 2020 Rising Star award by the LEAD national conference for women in hematology and oncology, the Mayo Brothers Distinguished Fellowship award, and the 2018 Resident of the Year Award by the National Hispanic Medical Association

Dr. Alexander Drilon is the Chief of the Early Drug Development Service and an Associate Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York. His research focuses on the development of targeted therapy for oncogene-driven cancers.

I am a medical oncologist at UT Southwestern specializing in the care of lung cancer patients. My laboratory, located in the Hamon Center for Therapeutic Oncology, focuses on translational research in small cell lung cancer (SCLC) and other aggressive neuroendocrine tumors. We leverage a large panel of patient-derived xenograft (PDX) models that closely recapitulate the clinical features of their corresponding patients to discover new targets and develop new therapies for this deadly disease. We have two current areas of focus: (1) strategies to overcome or circumvent chemotherapy cross-resistance, which renders relapsed SCLC refractory to further care, and (2) approaches to target loss of the retinoblastoma (RB1) tumor suppressor by synthetic lethality, a genomic hallmark of SCLC.

Afshin Dowlati, MD is Professor of Medicine and Oncology at Case Western Reserve University and the Associate Director for Clinical Research at the Case Comprehensive Cancer Center. He directs the early phase therapeutics and thoracic oncology programs and University Hospitals Seidman Cancer Center. His laboratory research focuses on the biology of small cell lung cancer. His laboratory identified the YAP1 positive subgroup of SCLC in 2017. He is the recipient of the NCI Michaele Christian Oncology Development Lectureship award in 2012 for his efforts in early phase clinical trials.

Dr. Doroshow is Assistant Professor of Medicine at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai. She divides her clinical practice and research between the Early Phase Trials Unit, where she sees patients with a variety of solid tumors on phase 1 and 2 trials of novel agents, and the Center for Thoracic Oncology, where she sees patients with lung cancer. Her research focuses on the use of targeted therapies to treat cancer and examines the use of novel agents to target DNA damage and repair processes.

I am a general thoracic surgeon, a professor in the Department of Surgery, and chief of the section of Thoracic Surgery at the University of Chicago. My research has focused on the discovery and validation of diagnostic and prognostic biomarkers for thoracic malignancies. My clinical and interests focus on the diagnosis and treatment of non-small cell lung cancer. Areas of clinical expertise include the use of multimodality therapy for thoracic malignancies, treatment options for high risk patients with early stage lung cancer and cancer in women.

Maximilian Diehn MD, PhD is the CRK Faculty Scholar and Associate Professor of Radiation Oncology at Stanford University. He is Vice Chair of Research of the Department of Radiation Oncology and Division Chief of Radiation and Cancer Biology. He received his Bachelor’s Degree in Biochemical Sciences from Harvard College and his M.D./Ph.D. in Biophysics from Stanford University. Dr. Diehn is a board certified Radiation Oncologist and specializes in the treatment of lung cancers. His research program spans laboratory, translational, and clinical studies. His main areas of interest include liquid biopsies, lung cancer biology, and mechanisms of resistance to anti-cancer therapies including radiotherapy, immunotherapy, and targeted therapies. He has served on committees for a variety of national organizations including NCI, ASCO, AACR, ASTRO and RSNA and is a Scientific Editor for Cancer Discovery. Dr. Diehn has received funding from organizations such as the NIH, Department of Defense, and Stand Up To Cancer and he has been recognized with a variety of awards, including the NIH Director’s New Innovator Award, the V Foundation Scholar Award, the Sidney Kimmel Scholar Award, the Doris Duke Clinical Scientist Development Award, and election into the American Society for Clinical Investigation.

Dr. Ibiayi Dagogo-Jack received her bachelor’s degree from Vanderbilt University and her medical degree from the University of Chicago Pritzker School of Medicine. She trained in internal medicine at Brigham and Women’s Hospital. Following residency, she completed hematology/oncology fellowship in the combined Massachusetts General Hospital/Dana Farber Cancer Institute program. She is a medical oncologist at Massachusetts General Hospital where she specializes in thoracic cancers and conducts clinical and translational research. Her research focuses on understanding mechanisms underlying response and resistance to novel targeted therapies, investigating the role of non-invasive assays in molecular surveillance, and developing clinical trials that evaluate novel drug combinations in lung cancer and mesothelioma.

Sanja Dacic is a professor of pathology in the Department of Pathology at the University of Pittsburgh , Director of Anatomic Pathology at UPMC Presbyterian Hospital and Director of Thoracic Pathology Center of Excellence . She is a member of the IASLC Pathology Committee.

Amy L. Cummings joined the thoracic oncology faculty at the David School of Medicine in 2020. Her interests include clinical trials, especially in early stage lung cancer, and applications of bioengineering to cancer genomics. She is part of the University of California Lung Cancer Consortium where she leads efforts around the use of clinical data.